[
  {
    "ts": null,
    "headline": "Novavax Stock Is Up Again. There Are Still Big Questions About the Fate of Its Covid Shot.",
    "summary": "Novavax Stock Is Up Again. There Are Still Big Questions About the Fate of Its Covid Shot.",
    "url": "https://finnhub.io/api/news?id=aee6216db9db89f81b52cb14e46050ab39a4f1c2b5c2e4a626b977ab1e868740",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745848200,
      "headline": "Novavax Stock Is Up Again. There Are Still Big Questions About the Fate of Its Covid Shot.",
      "id": 134149066,
      "image": "",
      "related": "MRNA",
      "source": "MarketWatch",
      "summary": "Novavax Stock Is Up Again. There Are Still Big Questions About the Fate of Its Covid Shot.",
      "url": "https://finnhub.io/api/news?id=aee6216db9db89f81b52cb14e46050ab39a4f1c2b5c2e4a626b977ab1e868740"
    }
  },
  {
    "ts": null,
    "headline": "Down 36%, Is Moderna a Buy on the Dip?",
    "summary": "With that, a major pandemic star -- biotech Moderna (NASDAQ: MRNA) -- also seems to be disappearing from the world's attention.  This doesn't mean Moderna is inactive; in fact, it's quite the opposite.  Moderna shot to prominence near the end of 2021, when its Spikevax coronavirus vaccine received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA).",
    "url": "https://finnhub.io/api/news?id=cda336d6f97342c8062a1c1fcd2ed717e109ccb4ce26d7461526b72380a996f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745835660,
      "headline": "Down 36%, Is Moderna a Buy on the Dip?",
      "id": 134115916,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "With that, a major pandemic star -- biotech Moderna (NASDAQ: MRNA) -- also seems to be disappearing from the world's attention.  This doesn't mean Moderna is inactive; in fact, it's quite the opposite.  Moderna shot to prominence near the end of 2021, when its Spikevax coronavirus vaccine received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA).",
      "url": "https://finnhub.io/api/news?id=cda336d6f97342c8062a1c1fcd2ed717e109ccb4ce26d7461526b72380a996f3"
    }
  },
  {
    "ts": null,
    "headline": "Moderna : AACR 2025 (KEYNOTE-942 INT/mRNA-4157 Phase 2 melanoma TCR dynamics)",
    "summary": "855Dynamics of T-Cell Receptors Following Intismeran Autogene Plus Pembrolizumab or Pembrolizumab Alone in Resected Melanoma From the mRNA-4157-P201 Trial Min Lu,1 Ryan J....",
    "url": "https://finnhub.io/api/news?id=728813ed7ca10ad3cb00f20c70fe061a21a258b3d31ce9bda54b1a3bb90e6c7f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745824940,
      "headline": "Moderna : AACR 2025 (KEYNOTE-942 INT/mRNA-4157 Phase 2 melanoma TCR dynamics)",
      "id": 134113212,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "855Dynamics of T-Cell Receptors Following Intismeran Autogene Plus Pembrolizumab or Pembrolizumab Alone in Resected Melanoma From the mRNA-4157-P201 Trial Min Lu,1 Ryan J....",
      "url": "https://finnhub.io/api/news?id=728813ed7ca10ad3cb00f20c70fe061a21a258b3d31ce9bda54b1a3bb90e6c7f"
    }
  }
]